96,442 Shares in ANI Pharmaceuticals Inc (NASDAQ:ANIP) Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. acquired a new position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 96,442 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,028,000.

Other hedge funds have also recently modified their holdings of the company. Tower Research Capital LLC TRC bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth $32,000. Usca Ria LLC bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth $34,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ANI Pharmaceuticals by 237.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock worth $65,000 after acquiring an additional 559 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth $92,000. Finally, Convergence Investment Partners LLC bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth $164,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Several research analysts have commented on the company. Guggenheim assumed coverage on ANI Pharmaceuticals in a report on Thursday, September 12th. They set a “buy” rating and a $76.00 target price on the stock. ValuEngine downgraded ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, November 7th. Raymond James cut their target price on ANI Pharmaceuticals from $82.00 to $75.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday. Finally, BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 22nd. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $85.00.

Shares of ANIP opened at $55.74 on Friday. The company has a market capitalization of $686.09 million, a PE ratio of 11.69 and a beta of 2.20. ANI Pharmaceuticals Inc has a 12 month low of $36.92 and a 12 month high of $86.96. The stock’s 50-day moving average price is $71.81 and its two-hundred day moving average price is $73.20. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.30.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.43 by ($0.20). The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $56.10 million. ANI Pharmaceuticals had a return on equity of 28.28% and a net margin of 7.58%. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.29 earnings per share. Equities research analysts predict that ANI Pharmaceuticals Inc will post 4.58 EPS for the current fiscal year.

In other news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $68.21, for a total value of $516,963.59. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 24.70% of the stock is owned by insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: Understanding Options Trading

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.